# **LUPIN LIMITED**

## **SAFETY DATA SHEET**

## **Section 1: Identification**

Material Enskyce<sup>™</sup>

**Desogestrel and Ethinyl Estradiol Tablets USP** 

0.15 mg/0.03 mg

Identified uses of the substance or

mixture

Pharmaceutical

Manufacturer Lupin Limited

Pithampur (M.P.) – 454 775

INDIA.

**Distributor** Lupin Pharmaceuticals, Inc.

111 South Calvert Street, Harborplace Tower, 21st Floor, Baltimore, Maryland 21202

**United States** 

Tel. 001-410-576-2000 Fax. 001-410-576-2221

# **Section 2: Hazard(s) Identification**

### Classification of the substance or mixture

Carcinogenicity, Category 1A H350: May cause cancer

Reproductive toxicity, Category 1B H360FD: May damage fertility. May damage the unborn child.

Specific target organ toxicity - repeated exposure, Category 1

H372: Causes damage to organs through prolonged or repeated

exposure.

Long-term (chronic) aquatic hazard,

Category 1

H410: Very toxic to aquatic life with long lasting effects.

Label elements

**Hazard pictograms** 





Signal word Danger

**Hazard statements** H350 May cause cancer.

H360FD May damage fertility. May damage the unborn child.

H372 Causes damage to organs through prolonged or repeated

exposure

H410 Very toxic to aquatic life with long lasting effects.

SDS: 083/05 Effective Date: 21/06/2024 **Precautionary statements** P201 Obtain special instructions before use.

P260 Do not breathe dust.

P273 Avoid release to the environment.

P280 Wear protective gloves/ protective clothing/ eye protection/ face

protection.

P308 + P313 IF exposed or concerned: Get medical advice/

attention. P391 Collect spillage

Hazardous components which must

be listed on the label:

Desogestrel Ethinylestradiol

Other hazards This substance/mixture contains no components considered to be

either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher. Dust contact with the eyes can lead to mechanical irritation. Contact with dust can cause mechanical irritation or drying of the skin. May form explosive dust-air mixture during processing, handling, or other means.

# **Section 3: Composition/Information on Ingredients**

## Section 3, Composition/information on ingredients

Ingredients	CAS No.	Ingredients	CAS No.
Desogestrel USP	54024-22-5	Col. Silicon Dioxide NF/EP	7631-86-9
Ethinyl Estradiol USP	57-63-6	Talc USP	14807-96-6
Lactose Monohyd NF/EP	10039-26-6	Magnesium Stearate	557-04-0
Vitamin E USP	10191-41-0	Starch NF/EP	9005-25-8
Povidone (K 30) USP/EP	9003-39-08	Stearic Acid NF 50	57-11-4
Methyl Alcohol NF	67-56-1	Purified Water USP	7732-18-5

<sup>\*</sup> The exact percentage composition of this mixture has been withheld as a trade secret.

## **Section 4: First-Aid Measures**

General advice In the case of accident or if you feel unwell, seek medical advice

immediately.

When symptoms persist or in all cases of doubt seek medical advice.

Protection of first aiders

First Aid responders should pay attention to self-protection and use the

First Aid responders should pay attention to self-protection and use the recommended personal protective equipment when the potential for

exposure exists.

Inhaled If inhaled, remove to fresh air. Get medical attention.

Skin contact In case of contact, immediately flush skin with soap and plenty of

water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before

euse.

Eye contact If in eyes, rinse well with water. Get medical attention if irritation

develops and persists

If swallowed, DO NOT induce vomiting. Get medical attention. Rinse

mouth thoroughly with water.

SDS: 083/05

Effective Date: 21/06/2024

# **Section 5: Fire-Fighting Measures**

Specific hazards during firefighting Avoid generating dust; fine dust dispersed in air in sufficient

concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a

hazard to health.

**Extinguishing Media** Water spray, carbon dioxide, dry chemical powder or appropriate

foam.

circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire

area if it is safe to do so. Evacuate area.

Hazardous Combustion Products Hazardous combustion or decomposition products are expected when

the product is exposed to fire.

## **Section 6: Accidental Release Measures**

Personal Precautions Wear protective clothing and equipment consistent with the degree of

hazard.

**Environmental Precautions**Avoid release to the environment. Prevent further leakage or spillage if

safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be

contained.

Clean-up Methods Sweep up or vacuum up spillage and collect in suitable container for

disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup

of releases.

## **Section 7: Handling and Storage**

Handling Keep container tightly closed. Minimize dust generation and

accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Do not eat, drink or smoke when using this product.

Storage Store at 25°C (77°F); excursions permitted to 15° to 30°C

(59° to 86°F). [See USP Controlled Room Temperature].

# **Section 8: Exposure Controls/Personal Protection**

Use closed processing systems or containment technologies to control at source (e.g., glove boxes/isolators) and to prevent leakage of compounds into the workplace. All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. No open handling permitted. Totally enclosed processes and materials transport systems are required. Operations require the use of appropriate containment technology designed to prevent leakage of compounds into the workplace.

SDS: 083/05 Effective Date: 21/06/2024

## **Section 9: Physical and Chemical Properties**

#### **Physical Form** Enskyce Tablets are available in a blister (NDC 68180-739-71)

containing 28 tablets packed in a pouch (NDC 68180-739-71). Such three pouches are packaged in a carton (NDC 68180-739-73).

Each blister contains 28 film-coated tablets in the following order:

- Each of the 21-light orange, round, biconvex, film-coated tablet contains 0.15 mg of desogestrel and 0.03 mg of ethinyl estradiol USP and is debossed with "L" on one side and "J7" on the other side.
- Each of the 7 green, mottled, round, biconvex tablet debossed with "LU" on one side and "L22" on the other side.

Odour No data available Ηq No data available Melting point/freezing point No data available Initial boiling point and boiling range No data available Flash point No data available Evaporation rate No data available Flammability (solid, gas) No data available Flammability (liquids) No data available Upper explosion limit / Upper No data available

flammability limit

Lower explosion limit / Lower

flammability limit No data available Vapour pressure Relative vapour density No data available Relative density No data available Solubility(ies) Water solubility No data available partition coefficient: n octanol/water No data available Auto-ignition temperature No data available Decomposition temperature No data available Viscosity Viscosity, kinematic No data available Explosive properties No data available Not explosive No data available

# **Section 10: Stability and Reactivity**

No data available

Stability Stable under normal conditions. Reactivity Not classified as a reactivity hazard.

Hazardous reactions May form explosive dust-air mixture during processing, handling or

other means. Can react with strong oxidizing agents.

Conditions to avoid Heat, flames and sparks. Avoid dust formation.

Hazardous decomposition products No hazardous decomposition products are known.

Effective Date: 21/06/2024

SDS: 083/05 Page 4 of 6

# Section 11: Toxicological Information

Details	Desogestrel	Ethinyl Estradiol
Information on likely route of exposure	Oral	Oral
Inhalation	No adverse effects due to inhalation are expected.	The material is not thought to produce either adverse health effects or irritation of the respiratory tract following inhalation.
Skin Contact	Prolonged skin contact may cause temporary irritation.	Prolonged skin contact may cause temporary irritation.
Ingestion	Vomiting, diarrhea, water retention, sodium retention, gastrointestinal discomfort, mental depression, amenorrhea, insomnia, impaired glucose tolerance, pulmonary embolism Target Organs: Uterus (including cervix), Mammary gland.  Direct contact with eyes may cause	Nausea and vomiting, undesirable uterine growth, proliferation and withdrawal bleeding or loss of periods. It causes enlargement of the breasts in males. Other side effects include weight gain, swelling, breast tenderness, liver dysfunction, jaundice, depression, headache, and dizziness. Growth may be stunted due to premature closing of the growth plates. Skin reactions can include excess pigmentation of the face, rashes, and hives. Redness, itching and blistering has also been reported.  Direct contact with eyes may cause
Eye Contact	temporary irritation.	temporary irritation.
Acute Toxicity	LD <sub>50</sub> (Rat oral, male and female): > 2,000 mg/kg. LD <sub>50</sub> (Mouse oral, male and female): > 2,000 mg/kg.	Mouse- Oral LD₅₀ 1737 mg/kg. Rat - Oral LD₅₀ 1200 mg/kg.
Respiratory/ Skin Sensitization	No sensitizing effects known.	No sensitizing effects known.
Mutagenicity	Negative Bacterial reverse mutation assay (Ames) and Micronucleus test.	<ul> <li>Negative in Bacterial Mutagenicity (Ames) Salmonella.</li> <li>Positive in Chromosome Aberration Human Lymphocytes.</li> <li>Positive in Sister Chromatid Exchange Human Lymphocytes.</li> <li>Positive Chromosome Aberration Chinese Hamster Ovary (CHO) cells.</li> <li>Positive in Vivo Micronucleus Mouse Bone Marrow</li> </ul>
Carcinogenicity	Suspected of causing cancer.	Suspected of causing cancer.
Reproduction toxicity	May damage fertility. Suspected of damaging the unborn child.	Laboratory experiments have shown teratogenic effects. Overexposure may cause reproductive disorder(s) based on tests with laboratory animals.
Cytotoxicity	Not Available	Cytotoxicity in isolated rat hepatocytes.

# Section 12: Ecological Information

No relevant studies identified.

# **Section 13: Disposal Considerations**

SDS: 083/05 Effective Date: 21/06/2024 Incinerate in an approved facility. Follow all federal state and local environmental regulations.

## **Section 14: Transport Information**

## IATA/ICAO - Not Regulated

IATA Proper shipping Name : N/A
IATA UN/ID No : N/A
IATA Hazard Class : N/A
IATA Packaging Group : N/A
IATA Label : N/A

## **IMDG** - Not Regulated

IMDG Proper shipping Name:N/AIMDG UN/ID No:N/AIMDG Hazard Class:N/AIMDG Flash Point:N/AIMDG Label:N/A

### **DOT** - Not Regulated

DOT Proper shipping Name : N/A
DOT UN/ID No : N/A
DOT Hazard Class : N/A
DOT Flash Point : N/A
DOT Packing Group : N/A
DOT Label : N/A

## **Section 15: Regulatory Information**

This Section Contains Information relevant to compliance with other Federal and/or state laws.

## **Section 16: Other Information**

The above information is believed to be correct but does not purport to be all-inclusive and shall be used only as a guide. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.

**Lupin** shall not be held liable for any damage resulting from handling or from contact with the above product. Lupin reserves the right to revise this SDS.

SDS: 083/05 Page 6 of 6

Effective Date: 21/06/2024